A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis.

Sung Hae ChangJae Bum JunYun Jong LeeTae Young KangKi Won MoonJi Hyeon JuSeong Wook KangIn Ah ChoiYong-Beom ParkSeung Geun LeeShin-Seok LeeNam Hun HeoEun Bong Lee

Published in: Rheumatology (Oxford, England) (2021)

Time to CU healing is comparable for ERA and PDE5i. ERAs are more effective in reducing new DU occurrence than PDE5is. CCBs may be effective as a background medication.

Keyphrases

systemic sclerosis
interstitial lung disease
risk assessment
healthcare
rheumatoid arthritis
idiopathic pulmonary fibrosis
metal organic framework
drug induced